Eli Lilly Set to Showcase Innovations at Morgan Stanley Global Healthcare Conference

Eli Lilly to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Eli Lilly and Company, known for its commitment to advancing healthcare, is set to take part in the prestigious Morgan Stanley 23rd Annual Global Healthcare Conference. Scheduled for September 8, 2025, this event promises to be a significant platform for discussing the future of healthcare and the innovative initiatives Lilly is spearheading.

Jacob Van Naarden, Lilly's Executive Vice President and the President of Lilly Oncology, alongside Dr. David Hyman, Lilly's Chief Medical Officer, will engage in an insightful fireside chat starting at 9:15 AM Eastern Time. This session aims to provide key takeaways regarding the current trends in healthcare and Lilly's strategic direction, particularly in oncology—a field that continues to evolve with groundbreaking treatments and technologies.

The conference serves as an important gathering for industry leaders, investors, and stakeholders, making it an ideal opportunity for Lilly to showcase its latest breakthroughs in medicine and commitment to patient care. A live audio webcast will be available through Lilly's investor website, allowing a broader audience to listen in and gain insights from the discussions. The recording of the session will remain accessible on the website for around 90 days, ensuring that the information shared reaches a wide demographic of interested parties.

About Eli Lilly

Founded nearly 150 years ago, Eli Lilly is a pharmaceutical company dedicated to making life better for people around the world. The company leverages its expertise in biotechnology, chemistry, and genetic medicine to address some of the most pressing health challenges faced by society today. With a diverse range of medications that treat chronic conditions, including diabetes, obesity, and various forms of cancer, Lilly's commitment to innovation has had a profound impact on the lives of millions globally.

Lilly is not only focused on developing drugs; they are also pioneers in conducting clinical trials that reflect the diverse demographics of the population, ensuring that their findings are relevant and beneficial to everyone. This commitment to inclusivity in clinical research highlights Lilly’s broader role in promoting health equity across communities.

The company places significant emphasis on making its innovations accessible and affordable, striving to ensure that the benefits of their discoveries reach everyone in need.

To explore more about Eli Lilly, please visit Lilly’s Official Website and follow them on their social media platforms, including Facebook, Instagram, and LinkedIn. With a driven mission of improving health outcomes, Eli Lilly remains steadfast in its purpose to enhance the quality of life for millions around the world.

In conclusion, Lilly's participation in the Morgan Stanley Global Healthcare Conference is not just an opportunity to discuss current therapies but is a reflection of their ongoing commitment to innovation and patient care. The dialogues during this event could very well shape future directions in healthcare and pharmaceutical developments, making it a must-watch for anyone invested in the future of medicine.